<p><strong>Squamous Cell Carcinoma Of The Head And Neck (SCCHN)</strong>: Cetuximab&nbsp;is indicated in combination with&nbsp;radiation therapy&nbsp;for the initial treatment of locally or regionally advanced&nbsp;squamous cell carcinoma&nbsp;of the head and neck.<br />
<br />
Cetuximab is indicated in combination with platinum-based therapy with 5-FU for the first-line treatment of patients with recurrent locoregional disease or metastatic squamous cell&nbsp;carcinomaof the head and neck.<br />
<br />
Cetuximab, as a single agent, is indicated for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck for whom prior platinum-based therapy has failed.<br />
<br />
<strong>K-Ras Wild-Type, EGFR-Expressing Colorectal Cancer</strong>: Cetuximab is indicated for the treatment of&nbsp;K-Ras&nbsp;wild-type,&nbsp;epidermal growth factor receptor&nbsp;(EGFR)- expressing, metastatic&nbsp;colorectal cancer&nbsp;(mCRC) as determined by FDA-approved tests for this use&nbsp;</p>

<ul>
	<li>In combination with FOLFIRI (irinotecan, 5-fluorouracil,&nbsp;leucovorin) for first-line treatment</li>
	<li>In combination with irinotecan in patients who are&nbsp;refractory&nbsp;to irinotecan-based&nbsp;chemotherapy</li>
	<li>As a single agent in patients who have failed oxaliplatin- and irinotecan-based chemotherapy or who are intolerant to irinotecan.</li>
</ul>